Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Tyrosine kinase Inhibitors (Imatinib & Nilotinib).
- Who it may be relevant to
- Registry conditions: Chronic Myeloid Leukemia. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Impact of Tyrosine Kinase Inhibitors on Glucose and Lipid Metabolism in Chronic Myeloid Leukemia
Overview
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism
Detailed description
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism and how danger they drugs be
Interventions
- Drug Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
these drugs used in CML only
Primary outcome measures
- Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors [Time frame: Baseline and 3, 6, 9, and 12 months]
Secondary outcome measures (1)
- Change in lipid profile in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors [Time frame: Baseline and 3, 6, 9, and 12 months]
Eligibility criteria
Inclusion criteria
- CML patients free medical history
Exclusion criteria
- diabetic
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Hwang SM, Im SH, Rudra D. Signaling networks controlling ID and E protein activity in T cell differentiation and function. Front Immunol. 2022 Aug 2;13:964581. doi: 10.3389/fimmu.2022.964581. eCollection 2022. PMID 35983065
Identifiers
NCT: NCT07413263 · use of TKIs on CML